31/01/2026
This is the best news ❤️❤️❤️ So many CF sufferers who were not eligible (it would not benefit them) for the previous Vertex life saving/life changing medication can take this one. This really is the best news ever ❤️
We’re proud to share a major milestone for Australians living with cystic fibrosis.
From 1 February 2026, Alyftrek will be listed on the PBS, making this next-generation treatment more accessible to eligible Australians aged six and over.
Alyftrek combines three active ingredients - vanzacaftor, tezacaftor and deutivacaftor - to target the genetic cause of CF. As the first once-daily CFTR modulator, it helps control mucus production, supports lung and digestive health, and may make daily treatment routines easier to manage.
This achievement belongs to our entire community.
Thank you to the individuals, families, federation members and supporters who advocated alongside Cystic Fibrosis Australia, sharing your stories and insights to highlight why access to treatments like this truly matters.
Together, you made this possible, and we’ll continue working to ensure everyone living with CF can access the treatments they need to live full and productive lives.